A Role for Leukotriene Antagonists in Atopic Dermatitis?
- 42 Downloads
Atopic dermatitis is a chronic, relapsing skin condition that affects over 2% of the population. The pathophysiology of this disease is not completely understood, but immunologic abnormalities and the subsequent release of inflammatory mediators play a central role. Treatment with glucocorticoids has long been the standard of care, but their use is limited by their adverse effect profile. Leukotrienes (LTB4, LTC4, LTD4, and LTE4) are metabolites of arachidonic acid produced through the 5-lipoxygenase pathway. They play an important role in inflammatory and atopic conditions. LT modulating agents have been used with success in asthma. Recently, there has been increased interest in the potential utility of LT antagonists in atopic dermatitis. In vitro and in vivo data have demonstrated that LTs may play a key role in atopic dermatitis. The 2 different types of LT-modulating agents are 5-lipoxygenase inhibitors and LT receptor antagonists. Since the 5-lipoxygenase inhibitor acts at an earlier step in the LT synthetic pathway, it has the ability to alter the production of all the LTs, including LTB4, while the receptor antagonists target only the cysteinyl LTs, LTC4, LTD4, and LTE4. This reduction of LTB4 activity may point to a therapeutic advantage in using LT synthesis inhibitors as opposed to LT receptor antagonists for atopic dermatitis. Clinical evidence of the use of LT agents in atopic dermatitis is limited, but initial results have been promising and these agents may one day serve as corticosteroid-sparing treatments for atopic dermatitis.
KeywordsAtopic Dermatitis Allergic Rhinitis Montelukast LTB4 Zafirlukast
- 1.Champion R.H., Parish W.E. Atopic dermatitis. In: Rook A., Wilkinson D.S., Ebling F.J.G., editors. Textbook of dermatology. Oxford: Blackwell Scientific Publications, 1986: 419–434Google Scholar
- 2.Leung D.Y.M., Tharp M., Boguniewicz M. Atopic dermatitis. In: Freedberg I., Eisen A.Z., Wolff K., editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill, 1999: 1464–1480Google Scholar
- 4.Hanifin J., Chan S.C. Diagnosis and treatment of atopic dermatitis. Dermatol Ther 1996; 1: 9–18Google Scholar
- 7.Busse W.W. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998 Jun; 157 (6 Pt 2): S210–S213; discussion S247-8Google Scholar
- 9.Songzhu A., Goetzl E.J. Lipid mediators of hypersensitivity and inflammation. In: Middleton E., Ellis E.F., Yunginger J.W., editors. Allergy: principles and practice. St. Louis: Mosby-Year Book, 1998: 168–182 (C14)Google Scholar
- 10.Fischer A.R., Drazen J.M. Antileukotriene drugs in the treatment of asthma. In: Middleton E., Ellis E.F., Yunginger J.W., editors. Allergy: principles and practice. St. Louis: Mosby-Year Book, 1998: 678–684 (C49)Google Scholar
- 14.Ikai K., Okano H., Sakamoto Y., et al. Leukotriene A4 hydrolase in human skin and peripheral leukocytes. In: Abstracts of 8th International Congress of Immunology, Hungary, 1992: 454Google Scholar
- 16.Ruzicka T., Ring J. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema. Acta Dermatovener (Stockholm) 1987; 67: 469–475Google Scholar
- 22.Nakayama J., Kiryu H., Hori Y. Leukotriene B4 in patients with atopic dermatitis and other skin diseases: changes by an anti-allergic agent, azelastine hydrochloride. In: Proceeding of the 7th Korea-Japan Joint Meeting of Dermatology, Korea, 1991: 388–397Google Scholar
- 27.Yanase D.J., David-Bajar K.M. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. In: 58th Annual Meeting of American Academy of Dermatology: 2000 Mar 10–15. Poster abstract book. San Francisco: American Academy of Dermatology, 2000Google Scholar